Juan Jose Perez Ruixo
Juan Jose Perez Ruixo
Other namesJJ Perez-Ruixo, JJP Ruixo
Janssen Research & Development
Verified email at
Cited by
Cited by
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer
E Van Cutsem, H Van De Velde, P Karasek, H Oettle, WL Vervenne, ...
Journal of clinical oncology 22 (8), 1430-1438, 2004
Model evaluation of continuous data pharmacometric models: metrics and graphics
THT Nguyen, MS Mouksassi, N Holford, N Al‐Huniti, I Freedman, ...
CPT: pharmacometrics & systems pharmacology 6 (2), 87-109, 2017
Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer
S Rao, D Cunningham, A De Gramont, W Scheithauer, M Smakal, ...
Journal of Clinical Oncology 22 (19), 3950-3957, 2004
Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma
SJ Cohen, L Ho, S Ranganathan, JL Abbruzzese, RK Alpaugh, M Beard, ...
Journal of Clinical Oncology 21 (7), 1301-1306, 2003
Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer
SRD Johnston, T Hickish, P Ellis, S Houston, L Kelland, M Dowsett, ...
Journal of clinical oncology 21 (13), 2492-2499, 2003
Multi-dimensional function approximation and regression estimation
F Pérez-Cruz, G Camps-Valls, E Soria-Olivas, JJ Pérez-Ruixo, ...
International conference on artificial neural networks, 757-762, 2002
Pharmaceutical biotechnology: fundamentals and applications
DJA Crommelin, RD Sindelar, B Meibohm
Springer Science & Business Media, 2013
Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis
L Sutjandra, RD Rodriguez, S Doshi, M Ma, MC Peterson, GR Jang, ...
Clinical pharmacokinetics 50, 793-807, 2011
Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys
JJ Xiao, W Krzyzanski, YM Wang, H Li, MJ Rose, M Ma, Y Wu, B Hinkle, ...
The AAPS journal 12, 646-657, 2010
Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours
L Gibiansky, L Sutjandra, S Doshi, J Zheng, W Sohn, MC Peterson, ...
Clinical pharmacokinetics 51, 247-260, 2012
Clinical implications of complex pharmacokinetics for daratumumab dose regimen in patients with relapsed/refractory multiple myeloma
XS Xu, X Yan, T Puchalski, S Lonial, HM Lokhorst, PM Voorhees, ...
Clinical Pharmacology & Therapeutics 101 (6), 721-724, 2017
Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects
YMC Wang, W Krzyzanski, S Doshi, JJ Xiao, JJ Pérez-Ruixo, AT Chow
The AAPS journal 12, 729-740, 2010
Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab
BB Yang, P Lum, A Chen, R Arends, L Roskos, B Smith, JJP Ruixo
Clinical pharmacokinetics 49, 729-740, 2010
A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy
SRD Johnston, VF Semiglazov, GM Manikhas, D Spaeth, G Romieu, ...
Breast cancer research and treatment 110, 327-335, 2008
Time Course of Bone Mineral Density Changes With Denosumab Compared With Other Drugs in Postmenopausal Osteoporosis: A Dose-Response–Based Meta-Analysis
JW Mandema, J Zheng, C Libanati, JJ Perez Ruixo
The Journal of Clinical Endocrinology & Metabolism 99 (10), 3746-3755, 2014
Population pharmacokinetics of rilotumumab, a fully human monoclonal antibody against hepatocyte growth factor, in cancer patients
M Zhu, S Doshi, PO Gisleskog, KS Oliner, JJ Perez Ruixo, E Loh, Y Zhang
Journal of pharmaceutical sciences 103 (1), 328-336, 2014
Prediction of cyclosporine dosage in patients after kidney transplantation using neural networks
G Camps-Valls, B Porta-Oltra, E Soria-Olivas, JD Martín-Guerrero, ...
IEEE Transactions on Biomedical Engineering 50 (4), 442-448, 2003
Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects
P Olsson-Gisleskog, P Jacqmin, JJ Perez-Ruixo
Clinical pharmacokinetics 46, 159-173, 2007
A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma
JE Rosenberg, H von der Maase, JD Seigne, J Mardiak, DJ Vaughn, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2005
Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin
K Jolling, JJP Ruixo, A Hemeryck, A Vermeulen, T Greway
European journal of pharmaceutical sciences 24 (5), 465-475, 2005
The system can't perform the operation now. Try again later.
Articles 1–20